Cellyan Biotechnology (HKPD) Non-Current Assets (2024 - 2025)
Cellyan Biotechnology (HKPD) reported Non-Current Assets of $776298.0 for Q3 2025, down 39.47% year-over-year from $1.3 million in Q3 2024, and up 12.48% quarter-over-quarter from $690171.0 in Q1 2025.
Cellyan Biotechnology (HKPD) Non-Current Assets (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Non-Current Assets data on file, last reported at $776298.0 in Q3 2025.
- Non-Current Assets for Q3 2025 came in at $776298.0, down 39.47% year-over-year; the trailing twelve-month figure through Sep 2025 was $776298.0 (down 39.47% YoY), and the FY2025 annual result was $690171.0, down 20.26% from the prior year.
- Non-Current Assets climbed to $776298.0 in Q3 2025 per HKPD's latest filing, from $690171.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.3 million in Q3 2024 and troughed at $690171.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | 193.66 Mn |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | 25.11 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 28.51 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | 18.63 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | 6.81 Bn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | 1.83 Bn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 20.59 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | 10.63 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | 25.48 Mn |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | 776,298.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 776,298.00 |
| Mar 31, 2025 | 690,171.00 |
| Sep 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 865,518.00 |